STOCKHOLM, Feb. 20, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic and its partner Bristol Myers Squibb (NYSE: BMY) have received clearance from the U.S. Federal Trade Commission (FTC) for BioArctic to out-license its...
Read More Details
Finally We wish PressBee provided you with enough information of ( BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing )
Also on site :
- Reform MP James McMurdock suspends himself from party over ‘business propriety during pandemic’
- Disturbed’s David Draiman Met with Some Boos at Final Black Sabbath Concert
- Trump wants more skilled tradespeople. His Labor Department is trying to cut off a pipeline of workers